These results mark an important first step in establishing the safety and efficacy of CRISPR/Cas9 for treating NSCLC, sarcoma, and potentially other cancers, given the pivotal role of the PD-1/PD-L1 axis in cancer immune evasion and therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.